Related references
Note: Only part of the references are listed.Are we repeating mistakes of the past? A review of the evidence for esketamine
Mark A. Horowitz et al.
BRITISH JOURNAL OF PSYCHIATRY (2021)
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Dawn F. Ionescu et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2021)
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Anees Bahji et al.
JOURNAL OF AFFECTIVE DISORDERS (2021)
The Effects of Ketamine on Cognition in Treatment-Resistant Depression: A Systematic Review and Priority Avenues for Future Research
Hartej Gill et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2021)
The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis
Jiaqi Xiong et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2021)
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3
Rachel Ochs-Ross et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2020)
Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials
Katrina Witt et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2020)
Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial
Yoav Domany et al.
DEPRESSION AND ANXIETY (2020)
Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study
Fernanda S. Correia-Melo et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression
Jennifer L. Phillips et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Disruptive treatments in psychiatry
Eduard Vieta
REVISTA DE PSIQUIATRIA Y SALUD MENTAL (2020)
A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial
Elias Dakwar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program
Teodora Doherty et al.
CNS DRUGS (2020)
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression
Naji C. Salloum et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
Maurizio Fava et al.
MOLECULAR PSYCHIATRY (2020)
Effects of Low-Dose Ketamine on the Antidepressant Efficacy and Suicidal Ideations in Patients Undergoing Electroconvulsive Therapy
Qibin Chen et al.
JOURNAL OF ECT (2020)
Ketamine normalizes subgenual cingulate cortex hyper-activity in depression
Laurel S. Morris et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Chadi G. Abdallah et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation
Jessica R. Gilbert et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2020)
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents
Matthew E. Klein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review
Meryem Grabski et al.
BEHAVIOURAL BRAIN RESEARCH (2020)
The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder
Roger S. McIntyre et al.
BIPOLAR DISORDERS (2020)
The identification, assessment and management of difficult-to-treat depression: An international consensus statement
R. H. McAllister-Williams et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments
Kyle T. Greenway et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2020)
New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others
Michele Protti et al.
MEDICINAL RESEARCH REVIEWS (2020)
Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials
Joanna Kryst et al.
PHARMACOLOGICAL REPORTS (2020)
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence
Nelson B. Rodrigues et al.
EXPERT OPINION ON DRUG SAFETY (2020)
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol
Jennifer L. Phillips et al.
BMC PSYCHIATRY (2020)
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
Markus Dold et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2020)
Opioid Receptor mu-1 and Ketamine Effects in a Suicidal Depression Trial A Post Hoc Exploration
Michael F. Grunebaum et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2020)
The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises
Jay Ching Chieh Wang et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2020)
Rapid acting antidepressants in the mTOR pathway: Current evidence
K. Athira et al.
BRAIN RESEARCH BULLETIN (2020)
Cost-Effectiveness of Esketamine Nasal Spray for Patients With Treatment-Resistant Depression in the United States
Eric L. Ross et al.
PSYCHIATRIC SERVICES (2020)
Urothelial toxicity of esketamine in the treatment of depression
Hannelore Findeis et al.
PSYCHOPHARMACOLOGY (2020)
Genome-wide association study and polygenic risk score analysis of esketamine treatment response
Qingqin S. Li et al.
SCIENTIFIC REPORTS (2020)
Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Chiara Gastaldon et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2020)
Burden of Treatment Resistant Depression (TRD) in patients with major depressive disorder in Ontario using Institute for Clinical Evaluative Sciences (ICES) databases: Economic burden and healthcare resource utilization
Roger S. McIntyre et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need
George Papakostas
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Double-Blind, Randomized Study (ASPIRE I)
Dong-Jing Fu et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2)
Ewa Wajs et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis
George Papakostas et al.
JOURNAL OF CLINICAL PSYCHIATRY (2020)
The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis
Roger S. McIntyre et al.
JOURNAL OF AFFECTIVE DISORDERS (2020)
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder
Marlene P. Freeman et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2020)
Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis
Ben Carter et al.
INTERNATIONAL REVIEW OF PSYCHIATRY (2020)
A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder
Kelly Perlman et al.
JOURNAL OF AFFECTIVE DISORDERS (2019)
Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial
Dawn F. Ionescu et al.
JOURNAL OF AFFECTIVE DISORDERS (2019)
Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression
Suzanne van Bronswijk et al.
PSYCHOLOGICAL MEDICINE (2019)
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol
Sanjay J. Mathew et al.
CONTEMPORARY CLINICAL TRIALS (2019)
Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial
Sara Costi et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function
Eric W. Lumsden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression
Alan F. Schatzberg
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Vanina Popova et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
A Word to the Wise About Intranasal Esketamine
Alan F. Schatzberg
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect
Boris D. Heifets et al.
JAMA PSYCHIATRY (2019)
A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial
Elias Dakwar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Esketamine for treatment resistant depression
Jennifer Swainson et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)
Maggie Fedgchin et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice
Lucie Bartova et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2019)
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression A Randomized Clinical Trial
Ella J. Daly et al.
JAMA PSYCHIATRY (2019)
More Thoughts on Intranasal Esketamine: Response to Drevets et al.
Alan F. Schatzberg
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Successful Use of Ketamine for the Treatment of Psychotic Depression in a Teenager
Paria Zarrinnegar et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2019)
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Nolan R. Williams et al.
MOLECULAR PSYCHIATRY (2019)
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression
Naji C. Salloum et al.
DEPRESSION AND ANXIETY (2019)
Fractionating Blunted Reward Processing Characteristic of Anhedonia by Over-Activating Primate Subgenual Anterior Cingulate Cortex
Laith Alexander et al.
NEURON (2019)
Association of Combined Naltrexone and Ketamine With Depressive Symptoms in a Case Series of Patients With Depression and Alcohol Use Disorder
Gihyun Yoon et al.
JAMA PSYCHIATRY (2019)
The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine
Balwinder Singh et al.
JOURNAL OF CLINICAL PSYCHIATRY (2019)
Oral Ketamine for Depression: A Systematic Review
Joshua D. Rosenblat et al.
JOURNAL OF CLINICAL PSYCHIATRY (2019)
Comparative Effect of Intravenous Ketamine and Electroconvulsive Therapy in Major Depression: A Randomized Controlled Trial
Gholamreza Kheirabadi et al.
ADVANCED BIOMEDICAL RESEARCH (2019)
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Samuel T. Wilkinson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Can a Framework Be Established for the Safe Use of Ketamine?
Robert Freedman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Efficacy of Esketamine in the Treatment of Depression With Psychotic Features: A Case Series
Elias Ajub et al.
BIOLOGICAL PSYCHIATRY (2018)
Rapid antidepressant effect of S-ketamine in schizophrenia
Lucie Bartova et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2018)
Concurrent use of ketamine and monoamine oxidase inhibitors in the treatment of depression: A letter to the editor
R. B. Katz et al.
GENERAL HOSPITAL PSYCHIATRY (2018)
Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression
Mark J. Niciu et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials
Joshua D. Rosenblat et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale
Gerrit I. van Schalkwyk et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Blood pressure safety of subanesthetic ketamine for depression: A report on 684 infusions
Patricio Riva-Posse et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Mechanisms of ketamine action as an antidepressant
P. Zanos et al.
MOLECULAR PSYCHIATRY (2018)
Region-specific Expression of NMDA Receptor GluN2C Subunit in Parvalbumin-Positive Neurons and Astrocytes: Analysis of GluN2C Expression using a Novel Reporter Model
Aparna Ravikrishnan et al.
NEUROSCIENCE (2018)
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Panos Zanos et al.
PHARMACOLOGICAL REVIEWS (2018)
Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study
Randall L. Morrison et al.
PSYCHOPHARMACOLOGY (2018)
Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder
Carola Rong et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2018)
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Nolan R. Williams et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Improving Depression Outcome by Patient-Centered Medical Management
A. John Rush et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Is There Really Nothing New Under the Sun? Is Low-Dose Ketamine a Fast-Acting Antidepressant Simply Because It Is An Opioid?
Mark S. George
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review
Yena Lee et al.
JOURNAL OF AFFECTIVE DISORDERS (2018)
Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior
Lai Fong Chan et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2018)
Side-effects associated with ketamine use in depression: a systematic review
Brooke Short et al.
LANCET PSYCHIATRY (2018)
Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation
Cristina Cusin et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2017)
S-ketamine compared to etomidate during electroconvulsive therapy in major depression
Maxim Zavorotnyy et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2017)
Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials
Elizabeth D. Ballard et al.
JOURNAL OF AFFECTIVE DISORDERS (2017)
The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use
C. Sophia Albott et al.
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Ketamine for Depression, 5: Potential Pharmacokinetic and Pharmacodynamic Drug Interactions
Chittaranjan Andrade
JOURNAL OF CLINICAL PSYCHIATRY (2017)
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression
Samuel T. Wilkinson et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2017)
Drugs of abuse and their metabolites in the urban rivers of Beijing, China: Occurrence, distribution, and potential environmental risk
Yan Zhang et al.
SCIENCE OF THE TOTAL ENVIRONMENT (2017)
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Gerard Sanacora et al.
JAMA PSYCHIATRY (2017)
New Medications for Treatment-Resistant Depression: A Brief Review of Recent Developments
Michael E. Thase
CNS SPECTRUMS (2017)
Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion
Steven J. Pennybaker et al.
BIOLOGICAL PSYCHIATRY (2017)
A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders
Samuel T. Wilkinson et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression
C. K. Loo et al.
ACTA PSYCHIATRICA SCANDINAVICA (2016)
A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression
Jaskaran B. Singh et al.
AMERICAN JOURNAL OF PSYCHIATRY (2016)
The Use of Ketamine for the Treatment of Depression in the Context of Psychotic Symptoms
Carolina Medeiros da Frota Ribeiro et al.
BIOLOGICAL PSYCHIATRY (2016)
Is Off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications
Melvyn W. Zhang et al.
BMC MEDICAL ETHICS (2016)
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Marko A. Peltoniemi et al.
CLINICAL PHARMACOKINETICS (2016)
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment A Procognitive Effect
Yena Lee et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2016)
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Panos Zanos et al.
NATURE (2016)
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Ronald S. Duman et al.
NATURE MEDICINE (2016)
Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression
Nick Ford et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2015)
Treating to target in major depressive disorder: response to remission to functional recovery
Roger S. McIntyre et al.
CNS SPECTRUMS (2015)
Possible pathophysiology of ketamine-related cystitis and associated treatment strategies
Jia-Fong Jhang et al.
INTERNATIONAL JOURNAL OF UROLOGY (2015)
Concomitant Benzodiazepine Use Attenuates Ketamine Response
Mark A. Frye et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2015)
The use of ketamine in electroconvulsive therapy
Wojciech Merk et al.
PSYCHIATRIA POLSKA (2015)
Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?
Gerard Sanacora et al.
NEUROPSYCHOPHARMACOLOGY (2015)
Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial
James W. Murrough et al.
NEUROPSYCHOPHARMACOLOGY (2015)
A Word to the Wise About Ketamine
Alan F. Schatzberg
AMERICAN JOURNAL OF PSYCHIATRY (2014)
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Kyle A. B. Lapidus et al.
BIOLOGICAL PSYCHIATRY (2014)
Do the dissociative side effects of ketamine mediate its antidepressant effects?
David A. Luckenbaugh et al.
JOURNAL OF AFFECTIVE DISORDERS (2014)
Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression
Mark J. Niciu et al.
JOURNAL OF CLINICAL PSYCHIATRY (2014)
Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response
James W. Murrough et al.
PSYCHOPHARMACOLOGY (2014)
Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder A Randomized Clinical Trial
Adriana Feder et al.
JAMA PSYCHIATRY (2014)
Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression
James W. Murrough et al.
BIOLOGICAL PSYCHIATRY (2013)
COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS
Roger S. McIntyre et al.
DEPRESSION AND ANXIETY (2013)
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Carolyn I. Rodriguez et al.
NEUROPSYCHOPHARMACOLOGY (2013)
The prevalence and natural history of urinary symptoms among recreational ketamine users
Adam R. Winstock et al.
BJU INTERNATIONAL (2012)
Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression
Xiaochen Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2012)
The Mu-Opioid Receptor and the NMDA Receptor Associate in PAG Neurons: Implications in Pain Control
Maria Rodriguez-Munoz et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study
Lobna Ibrahim et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Ronald S. Duman et al.
SCIENCE (2012)
Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression
Lobna Ibrahim et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2011)
Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study
Celia J. A. Morgan et al.
ADDICTION (2010)
A Randomized Add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Bipolar Depression
Nancy Diazgranados et al.
ARCHIVES OF GENERAL PSYCHIATRY (2010)
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
Sanjay J. Mathew et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Stuart A. Montgomery et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2009)
Cellular mechanisms underlying the antidepressant effects of ketamine:: Role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors
Sungho Maeng et al.
BIOLOGICAL PSYCHIATRY (2008)
Attentional bias to incentive stimuli in frequent ketamine users
C. J. A. Morgan et al.
PSYCHOLOGICAL MEDICINE (2008)
Post-synaptic action of morphine on glutamatergic neuronal transmission related to the descending antinociceptive pathway in the rat thalamus
Minoru Narita et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Ketamine-associated ulcerative cystitis: A new clinical entity
Rohan Shahani et al.
UROLOGY (2007)
Acute and chronic effects of ketamine upon human memory: a review
Celia J. A. Morgan et al.
PSYCHOPHARMACOLOGY (2006)
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine -: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists
A Anand et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Share Paper
